
zzso zzso and zzso zzso are zzso with profound zzso effects on zzso and natural killer zzso cell zzso zzso also zzso zzso killer zzso cell zzso in zzso Both zzso induce zzso activity against several zzso zzso This Phase I study of 50 patients assessed the zzso zzso tolerated dose zzso effects on certain immune zzso cells, zzso of zzso and development of zzso to the combination of zzso administered zzso and zzso administered zzso zzso was zzso zzso reduced the zzso and severity of fever and was necessary to prevent it from becoming zzso zzso occurred but never required zzso or produced zzso Constitutional symptoms, local skin toxicity at the site of zzso injection, generalized zzso zzso zzso and vomiting were also zzso One patient had zzso zzso zzso Two patients experienced drug-related zzso without evidence of zzso leak zzso neither required zzso zzso retention and zzso were not zzso The zzso was 5 zzso zzso zzso zzso of zzso and 2 zzso zzso zzso zzso of zzso when given in zzso Enhancement of in zzso zzso cell zzso and proliferation of zzso zzso and zzso cells zzso In zzso induction of zzso cell zzso was observed in three zzso Four patients developed zzso zzso zzso zzso but none developed zzso to zzso Peak zzso serum levels typically occurred 4 h following drug zzso zzso levels were within a factor of 3 of the peak level in the period zzso zzso h zzso No complete responses zzso One patient with zzso cancer and one with transitional cell zzso each had a partial response, and 13 other patients (5 with zzso cell, 4 with zzso and 4 other zzso had stable zzso zzso of zzso cell zzso was seen more commonly in patients with stable disease than in those with progressive zzso Combined administration of these agents is feasible with acceptable zzso and Phase II trials are zzso 

